, Columnist
Teva Fights Back at the Haters
It says pricing's not a problem; it needs to be right.
This article is for subscribers only.
It's not a good time to be generic. Firms such as Endo International have reported a worsening generic-drug pricing environment in the U.S., blaming it for softness in their business.
Teva, the world's biggest generic-drug maker, said on its first-quarter earnings call on Monday that the wave of price erosion its competitors cite is not all that bad. The company -- which is trying to close a $40.5 billion deal for Allergan's generics business in June -- said its generic prices fell by 4 percent in the U.S. last year, and it expects another 4 percent decline this year.